苦参碱联合恩替卡韦抗乙型肝炎病毒感染的作用及其机制

目的:探讨苦参碱联合恩替卡韦治疗乙型肝炎病毒(HBV)感染的疗效并初步探讨其作用机制。方法:选择2014年9月-2016年8月我院收治的HBeAg阳性乙肝患者98例,按治疗方法分为对照组和观察组,每组49例。对照组患者给予恩替卡韦治疗,观察组患者在对照组基础上应用苦参碱联合治疗。分别在治疗后12、24、48周观察和比较两组患者的HBeAg转阴率、ALT复常率、HBV DNA转阴率、血清球蛋白水平。结果:观察组在治疗后24、48周的HBeAg转阴率、ALT复常率、HBV DNA转阴率均显著高于对照组,差异均具有统计学意义(P0.05)。观察组血清球蛋白水平明显高于对照组,差异有统计学意义(P0.05)。两组间不良反应发生情况比较差异无统计学意义(P0.05)。结论:苦参碱联合恩替卡韦对于HBV具有较好的协同治疗作用,且安全性较好,可能与苦参碱降低血清转氨酶水平,增强患者免疫功能有关。

Effects of Matrine Combined with Entecavir on Hepatitis B Virus Infection and Its Mechanisms

ABSTRACT Objective: To explore the effect and mechanism of matrine combined with entecavir on HBV. Methods: From Septem- ber 2014 to August 2016, 98 cases of HBeAg positive hepatitis B patients in our hospital were selected as the study subjects, and they were divided into the control group and the observation group by treatment methods, 49 cases in each group. Patients in the control group were treated with entecavir, and patients in the observation group were treated with matrine combined with entecavir. At 12, 24 and 48 weeks after treatment, the HBeAg conversion rate, ALT recovery rate, HBV DNA conversion rate and serum globular protein level were observed and compared between the two groups. Results: The conversion rate of HBeAg, ALT and HBV DNA in the observation group were higher than those in the control group at 24 and 48 weeks after treatment(P<0.05). The level of serum globulin in the observation group was higher than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions be- tween the two groups (P>0.05). Conclusion: Matrine combined with entecavir had a good synergistic therapeutic effect on HBV with high safety, it may be related to the reduction of serum aminotransferase levels and enhancement of immune function of patients with ma- trine.